Jim Cramer Praises Johnson & Johnson (JNJ)'s Drugs
Johnson & Johnson (NYSE:JNJ) is one of the biggest healthcare and pharmaceutical companies in the world.
Johnson & Johnson (JNJ)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Fisher Asset Management Ken Fisher | 8,446,408 | $1,566,133,122 | +3% | 0.57% |
| 2. | GQG Partners Rajiv Jain | 6,037,579 | $1,119,493,707 | +12138% | 1.72% |
| 3. | Marshall Wace LLP Paul Marshall And Ian Wace | 3,584,162 | $664,575,319 | +127% | 0.67% |
| 4. | Two Sigma Advisors John Overdeck And David Siegel | 2,346,243 | $435,040,377 | +460% | 0.87% |
| 5. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 2,314,470 | $429,149,027 | -6% | 0.27% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $145.53 | 100 | $14,553.00 | 250 | 2024-04-30 | Filing | |
| $147.22 | 1,000 | $147,220.00 | 1,000 | 2024-12-12 | Filing | |
| $127.69 | 500 | $63,843.00 | 16,030 | 2020-03-13 | Filing | |
| $141.28 | 5,000 | $706,399.00 | 5,000 | 2019-12-13 | Filing | |
| $139.68 | 3,000 | $419,040.00 | 3,000 | 2019-06-11 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $192.71 | 21,721 | $4,185,793.09 | 10,658 | 2025-10-17 | Filing | |
| $177.81 | 56,471 | $10,040,882.63 | 178,013 | 2025-09-04 | Filing | |
| $179.21 | 125,824 | $22,548,654.81 | 275,967 | 2025-08-22 | Filing | |
| $176.91 | 16,820 | $2,975,570.69 | 14,000 | 2025-08-15 | Filing | |
| $163.55 | 19,137 | $3,129,829.56 | 10,658 | 2025-07-17 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 236,618,586 | $43,873,818,217 | 0.66% | |
| 2. | 207,261,021 | $38,430,338,382 | 0.67% | |
| 3. | 58,640,856 | $10,873,224,633 | 0.65% | |
| 4. | 56,215,455 | $10,388,360,745 | 0.66% | |
| 5. | 31,590,952 | $5,857,594,320 | 4.88% |
News See All
Jim Cramer Recently Put These 18 Stocks Under a Microscope
“Look out, the year of magical investing may be drawing to a close. All this year, pretty much anybody who bought stocks connected to AI and the data center, well, you know, you made money.
Jim Cramer Discussed These 25 Stocks In An Important Show About AI Spending
In a recent appearance on CNBC's Squawk on the Street, Jim Cramer and co-host David Faber discussed one of the most important issues in the stock market right now.
Freedom Capital Downgrades Johnson & Johnson (JNJ) to Hold Despite Strong Q3 Results
On October 22, Freedom Capital Markets has lowered its rating on Johnson & Johnson (NYSE:JNJ) from Buy to Hold, even as it raised the stock’s price target from $180 to $190 f...
Best Retirement Portfolio for a 60-year-old
As a growing number of Americans approach retirement, many still have not fully considered how inflation and Social Security benefits could affect their long...
Jury Orders Johnson & Johnson (JNJ) to Pay $966M in Talc Verdict
Johnson & Johnson (NYSE:JNJ) is one of Ray Dalio’s latest top stock positions.
Johnson & Johnson's (JNJ) Stock Is Now Positioned To "Challenge Eli Lilly," Says Jim Cramer
Johnson & Johnson (NYSE:JNJ) announced yesterday that it would spin off its orthopedics business to allow it to become the largest firm of its kind in the world.
J&J Announces Second Major Spinoff, Plans to Separate Orthopedics Division
On October 14, the company announced that it will spin off its orthopedics division into a separate company within the next 18 to 24 months.
11 Defensive Healthcare Dividend Stocks To Buy Now
US healthcare stocks have been under mounting pressure this year, largely due to policies introduced by the Trump administration.
13 Stocks to Buy According to Billionaire Ray Dalio's Bridgewater Associates
“Expect deeper structural problems”. That was the sentiment echoed by Ray Dalio, the founder of the world's largest hedge fund by assets under management, Bridgewater Associates.